Parkinson's drug approved in new strength
A new strength of Stalevo, the combination drug from Orion Corp. and Novartis used to treat Parkinson's disease, has been approved by the FDA.
A new strength of Stalevo, the combination drug from Orion Corp. and Novartis used to treat Parkinson's disease, has been approved by the FDA. The 200-mg tablet will contain 50 mg carbidopa, 200 mg levodopa, and 200 mg entacapone and will offer physicians greater dosing flexibility for patients experiencing symptom reemergence due to end-of-dose "wearing off," according to the manufacturers. Stalevo is also available in 50-, 100-, and 150-mg strengths. The new 200-mg tablet will be available in pharmacies in October.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
